Clinical Trials

613 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT04628767 2026-04-17

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

249 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07100080 2026-04-16

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

596 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05691478 2026-04-15

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

1,122 enrolled

Sarcoma

Osteosarcoma

NCT07005102 2026-04-15

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

854 enrolled

Tumor-Agnostic

Neoplasms

NCT07106762 2026-04-15

Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

470 enrolled

Urinary Bladder Neoplasms

NCT07528495 2026-04-14

Eliminate

396 enrolled

Head and Neck Neoplasms

NCT07063745 2026-04-07

MountainTAP-29

590 enrolled

Thoracic

Lung Neoplasms

NCT07129993 2026-03-19

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

630 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06236438 2026-02-23

LIVIGNO-4

840 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06783140 2025-12-05

PLATINUM-CAN

10 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms

NCT04442022 2025-10-03

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06095141 2025-08-07

PTCA199-6

30 enrolled

Pancreatic Adenocarcinoma

NCT05893888 2025-06-15

Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma

40 enrolled

Squamous Cell Carcinoma of Head and Neck

NCT06214572 2025-04-11

RUGB

249 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms

NCT06493552 2025-04-03

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

700 enrolled

Carcinoma, Transitional Cell

NCT06037980 2025-02-17

PURITY

300 enrolled

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT06123884 2025-02-10

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

526 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT05255653 2024-11-29

RAINBO

1,615 enrolled

Gynecologic

Endometrial Neoplasms

NCT06288373 2024-10-30

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

440 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT06138028 2024-07-24

Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer

90 enrolled

Esophageal Squamous Cell Carcinoma

NCT05125055 2023-11-22

Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC

80 enrolled